ActiTide-AH3(Liquefied 1000) / Acetyl hexapeptide-8

Palapala noi

ʻO ka noiʻi ʻana i nā hana anti-wrinkle kumu i alakaʻi ʻia i ka loaʻa ʻana o ActiTide-AH3, he hexapeptide hou i hoʻomohala ʻia ma o ka ʻepekema ʻepekema mai ka hoʻolālā kūpono i ka hana GMP, me nā hopena maikaʻi.

Hāʻawi ʻo ActiTide-AH3 i ka pono e hōʻemi i ka wrinkle e like me ka Botulinum Toxin Type A, ʻoiai e pale ana i nā pilikia injection a hāʻawi i ka ʻoi aku ka maikaʻi o ke kumukūʻai.

Nā Pōmaikaʻi Hoʻomaʻemaʻe:
Hoʻemi ʻo ActiTide-AH3 i ka hohonu o ka wrinkle ma muli o ka ʻoki ʻana o ka ʻiʻo o ka maka, me nā hopena i ʻōlelo ʻia ma ka lae a me nā wrinkles periocular.

Mechanism o ka hana:
Hoʻomaka ka ʻoki ʻana i ka ʻiʻo ma ka hoʻokuʻu ʻana o ka neurotransmitter mai nā vesicle synaptic. ʻO ka paʻakikī SNARE - kahi hui ternary o VAMP, Syntaxin, a me SNAP-25 protein - he mea nui ia no ka vesic docking a me ka neurotransmitter exocytosis (A. Ferrer Montiel et al., JBC 1997, 272: 2634-2638). Ke hana nei kēia paʻakikī ma ke ʻano he makau cellular, hopu i nā vesicle a me ka hoʻoulu ʻana i ka membrane fusion.

Ma ke ʻano he mimetic o ka SNAP-25 N-terminus, hoʻokūkū ʻo ActiTide-AH3 me SNAP-25 no ka hoʻohui ʻana i ka paʻakikī SNARE, e hoʻololi ana i kāna hui. ʻO ka destabilization o ka paʻakikī SNARE e hoʻopilikia i ka vesicle docking a me ka hoʻokuʻu ʻana o ka neurotransmitter ma hope, e alakaʻi ana i ka hōʻemi ʻana o ka ʻiʻo a me ka pale ʻana i ka wrinkle a me ka hoʻokumu ʻana o ka laina.

ʻO ka ActiTide-AH3 kahi koho ʻoi aku ka palekana, ʻoi aku ka waiwai, a me ka ʻoluʻolu i ka Botulinum Toxin Type A. Hoʻopili ia i ke ala hoʻokumu wrinkle hoʻokahi akā e hoʻohana ʻia ma o kahi mīkini ʻokoʻa.